National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab plus Ipilimumab plus platinum-doublet chemotherapy (Opdivo® plus Yervoy®) (1L NSCLC). HTA ID: 21014

Nivolumab plus ipilimumab plus platinum-doublet chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumours have no sensitising EGFR mutation or ALK translocation.

 

NCPE Assessment Process Complete
Rapid review commissioned 31/03/2021
Rapid review completed 30/04/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that nivolumab in combination with ipilimumab plus platinum-doublet chemotherapy not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.